Thursday’s biggest stock analyst calls like Nvidia

Here are Thursday’s biggest calls on Wall Street: Citi initiates Gilead Sciences as buy The firm said it’s bullish on the biotech company’s HIV franchise. “We are initiating coverage of Gilead with a Buy rating and a $125 TP.” Piper Sandler upgrades Campbell Soup to overweight from neutral Piper said it sees an attractive entry point for the stock. “We upgrade CPB from Neutral to Overweight on better long-term growth expectations with its Rao’s brand. It has improving US measured retail sales and volume trends (ex- SOVO acquired brands). Despite better trends, the stock has pulled back ~15% since mid- September, which we believe presents a good buying opportunity.” UBS initiates Cogent as buy The firm said it sees meaningful revenue acceleration for the internet services company. “We are initiating CCOI with a Buy rating and $102 PT. Oppenheimer reiterates Nvidia as buy The firm said it’s bullish heading into earnings next week. “We see NVDA best positioned in AI, benefiting from full-stack AI hardware/software. Reiterate Outperform and raise price target to $175 from $150.” Jefferies reiterates Tesla as hold The firm raised its price target on the stock to $300 per share from $195. “Tesla should take advantage of shares re-rating 30% back > $1trn since Trump’s election to raise equity. Assuming markets remain competitive, de-regulation raises the growth path but also the investment requirements for Tesla and competitors (AV, Robots) in ventures where returns remain unclear.” Bank of America upgrades ArcelorMittal to buy from Neutral Bank of America said the steel company’s valuation is “compelling.” ” ArcelorMittal is a leader in all major global steel markets, including automotive, construction, household appliances and packaging. Its industrial presence in Europe, Asia, Africa and America gives it exposure to all the key steel markets, from emerging to mature.” Morgan Stanley upgrades Doximity to equal weight from underweight Morgan Stanley said consensus estimates are too low for the online networking services for medical professionals. ‘Doximity is seeing renewed momentum in its business and conservative Q4 guidance suggests room for upward revisions to estimates.” Evercore ISI opens a negative tactical call on Target The firm said it sees sales trend deceleration heading into earnings next week. “We are initiating a negative TAP call on TGT ahead of its earnings on 11/20, with potential downside to $140.” KeyBanc downgrades Papa John’s to sector weight from overweight KeyBanc said it sees a slowing recovery for Papa John’s shares. “.We are downgrading shares of Papa Johns International from Overweight to Sector Weight, as our industry conversations suggest a recovery in sales trends and store-level profitability metrics could take longer than previously expected, and potentially require reinvestment on the part of the Company and its franchisees.” JPMorgan initiates BluePrint Medicines as buy JPMorgan said the biotech company is a “blockbuster franchise not fully valued.” “We initiate coverage on Blueprint Medicines ( BPMC) with an OW rating and a Dec 2025 PT of $126.” Compass Point upgrades BXP to buy from neutral Compass said the real estate investment trust is undervalued. “We are upgrading BXP to Buy with an $88 PT as this blue chip office has lagged its two Manhattan focused office peers by +30% YTD, despite having a better balance sheet and higher average quality office portfolio. As an investment grade credit, BXP has continuous access to the unsecured debt markets.” Wells Fargo reiterates Burlington as a top pick Wells said the off-price retailer remains a top pick heading into earnings later this month. ” BURL is likely to beat 3Q (w/ traffic accelerating into the exit).” JPMorgan reiterates Netflix as overweight The firm said investor sentiment remains robust on the streaming giant. “We believe investor sentiment remains strong into year-end on the 4Q content slate, along with confidence in NFLX meeting & beating its +11%-13% 2025 revenue outlook & 28% 2025 operating margin guide, while delivering meaningful FCF growth.” Barclays upgrades American Airlines to equal weight from underweight Barclays said it sees business travel improving and renegotiated card agreements for the airline. “We upgrade American to Equal Weight as balance sheet leverage fades, business travel share has room to improve and the carrier renegotiates co-brand card agreements in 2025.” Morgan Stanley reiterates Meta as overweight The firm said Meta is a major AI beneficiary. ” META’s scale and distribution have accelerated Meta AI adoption to levels comparable with ChatGPT and Gemini, despite only being released in April 2024.” Needham reiterates Amazon as buy Needham raised its price target on the stock to $250 per share from $210 after a series of channel checks. ” AMZN’s focus is on customer-centric innovation, and most of its product development comes directly from customer feedback. AMZN’s culture allows every FTE (full time equivalent) to pitch ideas and see them work-shopped, implemented and scaled quickly.” JPMorgan adds a negative catalyst watch on ResMed The firm said it’s keeping it’s overweight rating on ResMed but is concerned about a series of negatives catalysts in the months ahead for the sleep apnea company. “First, we expect Eli Lilly’s Zepbound label expansion to be granted by the FDA to include patients with obstructive sleep apnea (OSA), following the SURMOUNT-OSA trial results. Secondly, Novo Nordisk will release results from its phase 3 trial for CagriSema, a drug which offers weight loss of over 25%, a greater reduction than is offered by currently approved drugs.” Jefferies reiterates Microsoft as buy Jefferies said it’s getting even more bullish on the stock following a visit to company headquarters. “We believe MSFT can rerate as it continues to execute.”